Rosetta Genomics, Ltd. (NASDQ: ROSG) announced today that it has partnered with NYU Medical Center with the aim of developing a line of early detection diagnostic products for lung, and Mesothelioma cancers. The early detection test will mainly target over 45 million Americans who are at an increased risk of lung cancer due to smoking,
Archive for the 'NYU Medical Center' Category
Last update: March 06, 2014. 08:41:31 pm.